par Callie Weber | Sep 17, 2026 | Access to Care, NCD Partnerships, Actualités
Nigeria’s National Institute for Cancer Research and Treatment (NICRAT) has joined Innovative Medicines Access Programme (IMAP), following the signing of a Letter of Agreement with Bristol Myers Squibb (BMS) in August 2026. The agreement was signed in the presence of...
par E | Août 6, 2026 | Access to Care, Actualités
Reflections from the 2026 NCD Coalition Annual Meeting in Nairobi There was no shortage of ambition at this year’s NCD Coalition Annual Meeting in Nairobi.Across three days of discussions, government representatives, development partners, researchers, patient...
par E | Mai 7, 2026 | Access to Care, NCD Solutions, Actualités, Uncategorized
The devices are available. The prices are negotiated. So why aren’t patients benefiting? Across low- and middle-income countries (LMICs), significant progress has been made in expanding access to noncommunicable disease (NCDs) diagnostics. Devices have been sourced....
par E | Avr 9, 2026 | Access to Care, NCD Partnerships, Actualités
As a member of the UICC-led ATOM Coalition, NCDconnect has partnered with Bristol Myers Squibb (BMS) and Coalition partners to help implement BMS’ Innovative Medicines Access Program (IMAP). NCDconnect plays a critical role in this by designing country-specific...
par E | Oct 23, 2025 | Access to Care, NCD Solutions, Actualités
Rituximab, a life-saving monoclonal antibody used in the treatment of blood cancers, is now available as a biosimilar through NCDconnect, ensuring quality, affordability, and access to targeted cancer therapies across low- and middle-income countries (LMICs). Pharmacy...
par E | Juil 15, 2025 | Access to Care, NCD Solutions, Actualités
The collaboration between IDA Foundation’s NCDconnect initiative and the Access to Oncology Medicines (ATOM) Coalition, led by the Union for International Cancer Control (UICC), is making significant strides toward improving access to cancer care in low- and...
